2020 Lung Cancer Updates Spotlight on Clinical Oncology

2020 Lung Cancer Updates Spotlight on Clinical Oncology

User Photo
moasc

4 months
27 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Sai-Hong Ignatius Ou, MD PhD Health Science Clinical ProfessorChao Family Comprehensive Cancer Center University of California Irvine School of Medicine discusses these topics. NSCLC treatment options (circa February 2020 updated May 2020)Targeted therapy (FDA Approved indication)EGFR classical mutationsEGFR uncommon mutationsALK fusionROS1 fusionBRAF V600EMETex14+ NSCLC (Approved May 6, 2020)RET fusion (Approved May 8, 2020)Immunotherapy (FDA approved)Chemotherapy + IO for first-line treatment of Non-Sq NSCLC, Sq NSCLC, and SCLC. (PD-L1 expression agnostic)Single agent second line (PD-L1 expression agnostic)Chemotherapy (FDA approved)Chemo + anti-angiogenesis mAb (non-Sq NSCLC)Chemo + anti EGFR mAb (Sq NSCLC)Single agent + anti-angiogenesis mAb

Sponsors:

AbbVie 

AMAG

AstraZeneca 

Bayer 

BeiGene 

Clovis Oncology

Coherus 

Daiichi-Sankyo 

Dova Pharmaceuticals 

Foundation Medicine 

Jazz Pharmaceuticals  

Merck 

Pfizer Oncology 

Puma Biotechnology 

Tempus 

Verastem oncology

Walgreens 

Up Next Autoplay